Curriculum vitae

Prof. Dr. med. Nina Caroline Ditsch
born on October 31, 1974 in Ludwigshafen am Rhein

Professional activity and training

Since October 1, 2019	Head of breast center and managing senior physician Department of Gynecology and Obstetrics, University Hospital Augsburg; Germany
01/01/2014 – 09/30/2019	Surgical management leadership breast center, Ludwig Maximilians University (LMU) Munich; Germany
01/01/2007 – 09/30/2019	Head of Gynecological-Oncological Genetics, LMU Munich; Germany
11/01/2008 – 09/30/2019	Senior Physician at the Clinic and Polyclinic for Gynecology and Obstetrics LMU Munich - Campus Grosshadern; Germany
11/01/2002 – 09/30/2019	Scientific assistant at the Hospital of the LMU Munich Gynaecology and Obstetrics; Germany
Since 11/08/2016	Master of Senology (breast surgeon of AWOgyn)
05/18/2015	Certification as specialist on Gynecological Oncology
Since 02/01/2015	Mamma senior surgeon (DKG / DGS)
07/18/2012	Qualification for specialist genetic counseling
12/14/2006	Consultant in Gynecology and Obstetrics (exam)
11/01/2002	Approval as a doctor for medicine
May 2001 – October, 2002	Internship
10/01/1994 – 04/30/2001	Study of medicine at Ludwig Maximilians University, Munich and Johannes Gutenberg University, Mainz

Academic Qualifications

01/01/2021	W2 University professorship for operative and conservative senology
02/12/2018	Extraordinary professorship
06/19/2013	Habilitation, topic: New prognostic markers for breast cancer
01/09/2003	Doctorate: Surgical clinic and polyclinic of the LMU Munich Topic: Prognostic relevance of disseminated CK18-positive cells in the bone marrow nodal negative breast cancer patient and detection of the estrogen receptor (ÖR) on disseminated CK18-positive cells in the bone marrow of breast cancer patients, "Summa cum laude"

Education

1981 – 1985: Ernst Reuther primary school in Ludwigshafen

1985 – 1994: Ursulinen-Gymnasium in Mannheim, Abitur

Scientific Focus

- Prognostic and predictive factors in breast cancer
- Nuclear receptor studies on tumor tissue in breast cancer patients
- Importance of thyroid dysfunction based on blood tests in breast and ovarian cancer patients
- Individualization of cancer therapy with the help of biomarker-based, functional drug testing in a spheroid microtumor model (m4 top cluster / BMBF)
- Prognostic and predictive factors in ovarian cancer

Awards and Grants

02/26/2015	GBG (German Breast Group) Foundation: Poster award (750 €)
01/10/2014	Scholarship from the Weigand Foundation (12,000 €)
11/18/2011	Scholarship as part of the COMBATing Breast Cancer Conference (500 €)
2007 – 2012	Mentoring program of the Ludwig Maximilians University for excellent Scientists (headed by Prof. Dr. med. Ania Muntau)

Patent granted

04/2010	Early detection of a genetic disposition for breast and ovarian cancer with the help of the determination of thyroid hormone Receptors (B69074DE)

Memberships

- German Society for Senology (DGS)
- German Society for Gynecology and Obstetrics (DGGG)
- Project group breast cancer of the Munich Tumor Center (TZM)
- Working Group on Gynecological Laparoscopy (AGE)
- Professional Association of Gynecologists (BVF)
- Breast cancer Germany e.V.
- Mamazone
- Working Group Gynecological Oncology (AGO)
- Mentor in the German Medical Association for Women
- Board member EUBREAST

10 most relevant publications

1	*Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.* Cortazar P., Zhang L., Untch M., […] **Ditsch N.,** [...], Eiermann W., von Minckwitz G. **LANCET** Volume 384 Issue 9938 Page 164-172 DOI 10.1016/S0140-6736(13)62422-8; 2014
2	*Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.* Bojesen S., Pooley K.A., Johnarry S.E., […] **Ditsch N.,** [...], Chenevix-Trench G., Dunning A.M. **NATURE GENETICS** Volume 45 Issue 4 Page 371-384 DOI 10.1038/ng.2566; 2013
3	*Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer.* Rebbeck T.R., Mitra N., Wan F., […] **Ditsch N.,** [...], Hulick P.J., Andrulis I. **JAMA** Volume 313 Issue 13 Page 1347-1361 DOI 10.1001/jama.2014.5985; 2015
4	*Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.* Couch F.J., Wang X., McGuffog L., […] **Ditsch N.,** [...], Antoniou A.C., CIMBA **PLOS GENETICS** Volume 9 Issue 3 Article Number e1003212 DOI 10.1371/journal.pgen.1003212; 2013
5	*Identification of six new susceptibility loci for invasive epithelial ovarian cancer.* Kuchenbaecker, K.B., Ramus S.J., Tyrer J., [...], Chenevix-Trench G. Ditsch N. as member of Consortium of Investigators of Modifiers of BRCA1 and BRCA2 **NATURE GENETICS** Volume 47 Issue 2 Page 164-171; 2015
6	*Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.* Milne R.L., Kuchenbaecker K.B., Michailidou K., […], **Ditsch N.,** [...], Simard J. **NATURE GENETICS** Volume 49 Issue 12 Page 1767-1778 DOI 10.1038/ng.3785; 2017
7	*Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.* Rebbeck T.R., Friebel T.M., Friedmann E., […] **Ditsch N.,** [...], Antoniou A.C., Nathanson K.L. **HUMAN MUTATION** Volume 39 Issue 5 Page 593-620 DOI 10.1002/humu.23406; 2018
8	*Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.* Kast K., Rhiem K., Wappenschmidt B., […] **Ditsch N.,** [...], Schmutzler, R.K., Engel C.. German Consortium for Hereditary Breast and Ovarian Cancer. **JOURNAL OF MEDICAL GENETICS** Volume 53 Issue 7 Page 465-471 **DOI** 10.1136/jmedgenet-2015-103672; 2016
9	*Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.* Lecarpentier J., Silvestri V., Kuchenbaecker K.B., […] **Ditsch N.,** [...], Antoniou A.C., Ottini L. **JOURNAL OF CLINICAL ONCOLOGY** Volume 35 Issue 20 Page 2240-+ **DOI** 10.1200/JCO.2016.69.4935; 2017
10	*The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.* Rhiem K., Engel C., Graeser M., […] **Ditsch N.,** [...], Meindl A., Schmutzler R.K. **BREAST CANCER RESEARCH** Volume 14 Issue 6 Article Number R156 DOI 10.1186/bcr3369; 2012

Augsburg, den 21.01.2025

Faksimile - Unterschrift